Drug Trial Radar · NCT07389460
Intravenous rhPro-UK Before Stroke Thrombectomy in the Extended Time Window (BRIDGE-PUK EXTEND)
Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
820
Planned (sponsor's estimate)
Start
Apr 7, 2026
Primary completion
Dec 31, 2027
Study completion Mar 31, 2028
Sponsor
- Lead sponsor
- First Affiliated Hospital Xi'an Jiaotong UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Tasly Pharmaceutical Group Co., Ltd; Peking Union Medical College Hospital
- First posted
- Feb 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized, double-blind, placebo-controlled phase III clinical trial aims to evaluate the efficacy and safety of intravenous recombinant human Prourokinase (rhPro-UK) in acute ischemic stroke patients with large vessel occlusion presenting 4.5-24 hours after last known well. The study will address two primary questions: 1) Whether rhPro-UK enhances pre-thrombectomy reperfusion rates and improves 90-day functional outcomes compared to placebo; 2) Whether rhPro-UK increases the risk of symptomatic intracranial hemorrhage and mortality. Participants will be randomized to receive an intravenous bolus of rhPro-UK or matching placebo, with a total dose of 35mg (15mg administered as an intravenous push within 5 minutes, and the remaining 20mg continuously infused intravenously over 30 minutes). Key assessments include repeat neuroimaging (CT/CTA or MRI/MRA) at 24 hours post-treatment to evaluate reperfusion, NIH Stroke Scale score at day 5-7, and modified Rankin Scale score assessment at 90 days. Safety monitoring will focus on hemorrhagic transformation and mortality events throughout the study period.
Conditions
- Acute Ischemic Stroke
Interventions
Intravenous rhPro-UKDrug
Patients will receive intravenous rhPro-UK
Intravenous placeboDrug
Patients will receive intravenous placebo
Endovascular thrombectomyProcedure
Patients will receive endovascular thrombectomy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients functionally independent (mRS score 0 to 2) at 90 daysTime frame: 90 days post-randomization
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Xuanwu Hospital Capital Medical University
Beijing, China · Recruiting
The First Hospital of Lanzhou University
Lanzhou, Gansu, China · Recruiting
The Third Hospital of Hebei Medical University
Shijiazhuang, Hebei, China · Recruiting
Henan Provincial People's Hospital
Zhengzhou, Henan, China · Recruiting
Loudi Central Hospital
Loudi, Hunan, China · Recruiting
The Second Hospital of Dalian Medical University
Dalian, Liaoning, China · Recruiting
Qinghai Provincial People's Hospital
Xining, Qinghai, China · Recruiting
First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China · Recruiting
Shanxi Cardiovascular Hospital
Taiyuan, Shanxi, China · Recruiting
The First Affiliated Hospital of Shihezi University
Shihezi, Xinjiang Uygur Autonomous Region, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.